The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group receiving only supportive care. Rash was seen in 255 of the patients treated with cetuximab.

Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...

Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...

Cetuximab combined with chemotherapy significantly improves PFS and OS in mCRC patients, as confirmed by a meta-analysis of 25 studies. The study highlights cetuximab's efficacy, despite ...

We've seen a little bit of diarrhea as well with the anti-EGFR drugs that are already approved for colorectal cancer. Notably, Erbitux [cetuximab], Vectibix [panitumumab] are notorious for causing ...

and rash (2.1% each). Kopetz said the global phase III, randomized KRYSTAL-10 trial has completed enrollment and will compare the combination of adagrasib and cetuximab versus FOLFIRI or mFOLFOX6 ...